BC
RCUS icon

Bayforest Capital’s Arcus Biosciences RCUS Stock Holding History

Bayforest Capital’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$189K Buy
8,767
+799
+10% +$17.3K 0.21% 142
2025
Q4 		$190K Buy
+7,968
New +$163K 0.14% 304

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Bayforest Capital's RCUS Position: Q1 2026 in Review

Bayforest Capital increased its Arcus Biosciences (RCUS) stake by 10% in Q1 2026, buying an estimated $17.3K and bringing the position to 8,767 shares worth $189K. The position accounts for 0.21% of the portfolio, ranked #142.

Bayforest Capital first reported a position in RCUS in Q4 2025 and has held it in 2 quarters since. The position peaked at $190K in Q4 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Bayforest Capital held 8,767 shares of Arcus Biosciences worth $189K as of Q1 2026.
  • Bayforest Capital bought 799 Arcus Biosciences shares in Q1 2026, an estimated $17.3K.
  • Arcus Biosciences made up 0.21% of Bayforest Capital's portfolio in Q1 2026, its #142 holding.
  • Bayforest Capital first reported a position in Arcus Biosciences in Q4 2025 and has held it in 2 quarters since.
  • Bayforest Capital's Arcus Biosciences position peaked at $190K in Q4 2025.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Bayforest Capital's 13F filing for Q1 2026, filed 15 Apr 2026.